Key facts
- This page summarizes Frank Clyburn's Form 4 filing for Merck & Co., Inc. (MRK).
- 8 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2021, 18:16.
Frank Clyburn - 30 Oct 2021 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- EVP & Pres ? Human Health
- Issuer ticker
- MRK
- Reported as of
- 30 Oct 2021
- Net transaction value
- -$3,388,571
- SEC form
- 4
- Accepted by SEC
- 02 Nov 2021, 18:16:10 UTC
- Prior SEC filing
- 11 May 2021
- Next SEC filing
- 18 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez as Attorney-in-Fact for Frank Clyburn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Frank Clyburn filed Form 4 for Merck & Co., Inc. (MRK) on 02 Nov 2021.
Change
- Previous filing in this sequence was filed on 11 May 2021.
- Current net transaction value: -$3,388,571.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $207,622
- Shares
- +2,358
- Change %
- +2.5%
- Price
- $88.05
- Shares after
- 98,257
- Date
- 30 Oct 2021
- Ownership
- Direct
MRK
transaction
Common Stock
Tax liability
- Transaction value
- $102,314
- Shares
- -1,162
- Change %
- -1.2%
- Price
- $88.05
- Shares after
- 97,095
- Date
- 30 Oct 2021
- Ownership
- Direct
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +19,915
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 117,010
- Date
- 01 Nov 2021
- Ownership
- Direct
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +19,847
- Change %
- +17%
- Price
- $0.000000
- Shares after
- 136,857
- Date
- 01 Nov 2021
- Ownership
- Direct
MRK
transaction
Common Stock
Sale
- Transaction value
- $3,493,879
- Shares
- -39,762
- Change %
- -29%
- Price
- $87.87
- Shares after
- 97,095
- Date
- 01 Nov 2021
- Ownership
- Direct
- Footnotes
- F1, F2
MRK
holding
Common Stock - 401(k) Plan
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,780
- Date
- 30 Oct 2021
- Ownership
- By 401(k)
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -2,358
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 30 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,358
- Exercise price
- Footnotes
- F4, F5, F6
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -19,915
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,915
- Exercise price
- $43.65
- Footnotes
- F5, F7
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -19,847
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 19,848
- Date
- 01 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,847
- Exercise price
- $56.49
- Footnotes
- F5, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.8000 to $87.8950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Footnote F2
Holdings include shares acquired in dividend reinvestment transactions.
Footnote F3
Includes shares acquired and dividends earned through October 30, 2021 in the Merck U.S. Savings Plan, a 401(k) plan.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
Footnote F5
Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
Footnote F6
The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.
Footnote F7
The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.
Footnote F8
The option became exercisable in equal installments on 5/2/2015, 5/2/2016, and 5/2/2017.